AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Neuroendocrine Tumors. According to GlobalData, Phase II drugs for Neuroendocrine Tumors have a 28% phase transition ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

This new funding positions NRMA Insurance as the first corporate partner to support a McGrath Cancer Care Nurse since the ...

Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...

The late Malcolm Legget - who has become a MNZM for services to cardiology - used to say: "It is amazing what you can achieve ...

NRMA Insurance expands support for McGrath Foundation funding a 3rd McGrath Cancer Care Nurse NRMA Insurance has announced it ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief ...